top of page
Our Pipeline at a glance
We are developing targeted therapies addressing high-unmet-need cancers through a diverse and translational oncology pipeline.
Hematology Programs
Solid Tumor Programs
Autoimmune Diseases Programs
Development Programs – Hematology
GVT-HM-A101 is a next-generation, highly selective BTK inhibitor designed to achieve sustained target occupancy with minimal off-target effects. It aims to improve safety, including reduced cardiac risk, while providing durable suppression of B-cell receptor signaling in diseases such as CLL and mantle cell lymphoma.
MOLECULE
DISEASE AREA
INVESTIGATIONAL INDICATION
GVT-HM-A101
(BTK Inhibitor)
Hematologic Malignancies
TN CLL/SLL*
Treatment-Naive Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
AML/MDS (+ chemotherapy)
Acute Myeloid Leukemia/Myelodysplastic Syndrome
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
R/R FL (+CD20)*
— Relapsed/Refractory Follicular Lymphoma
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
Development Programs – Solid Tumors
GVT-53038, a PD-1 monoclonal antibody for lung cancer; GVT-C137, an FGFR2B antibody-drug conjugate targeting gastric cancer; and GVT-B455, a CCR8 monoclonal antibody for breast cancer. GVT-B455 also functions as a highly potent and selective CDK2 inhibitor, designed to block elevated Cyclin E/CDK2 activity—a key resistance pathway to standard CDK4/6 inhibitor therapies in HR+/HER2– breast cancer.
GVT-53038
(PD-1 Monoclonal Antibody)
Lung Cancers
Solid Tumors / Pan-Tumor,
Solid Tumors / Pan-Tumor, NSCLC — Non–Small Cell Lung Cancer
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
GVT-C137
(FGFR2B Antibody Drug Conjugate)
Gastrointestinal Cancers
GI Cancers
Gastric / Gastrointestinal Adenocarcinoma
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
GVT-B455
(CCR8 Monoclonal Antibody)
Breast/Gynecologic Cancers
HR+ Breast Cancer and Solid Tumors
HR+/HER2– Breast Cancer
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
Autoimmune/Immune and Inflammation
Genventis’s first-in-class targeted immunotherapy is engineered to modulate immune responses in autoimmune and inflammatory disorders. Developed by Genventis researchers, this therapy is designed to engage key immune pathways, promoting T-cell regulation, cytokine balance, and restoration of immune homeostasis to reduce chronic inflammation and tissue damage.
GVT-7012
(BTK Inhibitor)
Multiple Sclerosis
Relapsing and Progressive Multiple Sclerosis
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
GVT-7054
(IRAK4 Chimeric Degradation Activation Compound (CDAC))
Rheumatoid Arthritis
Moderate to Severe Rheumatoid Arthritis
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
GVT-7063
(JAK1 Inhibitor)
Inflammatory Bowel Disease
Ulcerative Colitis / Crohn’s Disease
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
The pipeline is updated quarterly. Last updated November 2025.
Safety and efficacy have not been established for investigational products and/or uses. .
* Four compounds are under the approval process in at least one major market, including the USA, EU, China, or Japan, and one compound is in ** Phase 1 confirmatory development.
bottom of page